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Background: A lot of prospective and retrospective studies focused on statin therapy
as a speciﬁc prophylactic measure of contrast-induced nephropathy. Although these
trials studied the role of different types of statins (atorvastatin, simvastatin and pra-
vastatin) in prevention of contrastinduced nephropathy, few studies tested the role of
rosuvastatin. In this current study, the aim was to assess the efﬁcacy of short-term
high-dose rosuvastatin pretreatment therapy for the prevention of contrast induced
nephropathy.
Methods: This study prospectively included two hundred patients who underwent
coronary angiography, and were randomized into two groups: control group (included
100 patients who did not receive statin therapy) and statin group (included 100 pa-
tients who received rosuvastatin 20 mg/day 3 days before and 7 days after coronary
angiography). According to recommendations of the National kidney foundation,
results had been recorded using both serum creatinine and glomular ﬁlteration rate
levels.
Results: There was statistically signiﬁcant reduction in the incidence of contrast-
induced nephropathy in rosuvastatin pretreated patients (“22%” and “15%” of them
developed contrast-induced nephropathy regarding the glomular ﬁlteration rate and
serum creatinine levels respectively), compared to those in the control group (“35%”
and “38%” regarding the glomular ﬁlteration rate and serum creatinine levels
respectively) with P value (<0.001 regarding serum creatinine and <0.042 regarding
glomular ﬁlteration rate).
Conclusion: Although the results of some clinical studies to prevent contrast-induced
nephropathy using statin pretreatment are conﬂicting, the current study coincided with
several clinical studies in favoring statin pretreatment for preventing contrast induced
nephropathy in patients undergoing coronary angiography. R
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Promising Results of Stent Boost Assisted Modiﬁed Minicrush Technique for
Treating Bifurcation Lesions
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Background: How Large, How much Important and the Disease Status of the Side
Branch (SB).
Methods: Total 50 patients were studied with a one year follow-up. The Stenting was
done by using modiﬁed Minicrush bifurcation technique assisted by stent boost.
Technique: Side branch (SB) stent positioned 2mm into main branch (MB), with MB
balloon centering the carina of SB. The SB stent (DES) dilated at nominal pressure,
check injection given to look for dissection distal edge of SB stent. The ﬂoppy wire
and balloon removed from the SB, then in MB - dilation given with NC balloon at
14 atm. Then MB (DES) of approximate size is deployed at nominal pressures .The
projection of SB stent in to MB is checked by stent boost. SB is re crossed with a
ﬂoppy wire from the distal cell of stent strut. The serial balloon dilatation with up
sizing balloon was given at the SB Ostial to expand the struts. A sequential kissing
balloon dilatation was also given with non compliant (NC) balloons of suitable size at
14 atms and simultaneous ﬁnal kissing done at 10 atms. A stent boost done with
kissing balloon in place. Check injections given to check stent apposition and TIMI III
ﬂow.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAResults:Conclusion: The stent boost assisted modiﬁed Minicrush technique, study of 50
patients with one year follow up we observed no incidence of acute vessel closure or
stent thrombosis. The 6% percent of these patients were required repeat revasculari-
zation at one year follow up. Stent boost is a cost effective tool to visualize exact SB
stent strut position at places where other imaging modalities IVUS, OCT are un-
available. Thus the stent boost assisted Minicrush technique looks to be promising,
easy to adapt for treating bifurcation lesions.
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Background: Several studies reported that clinical SYNTAX (Synergy between
Percutaneous Coronary Intervention (PCI) with TAXUS and Cardiac Surgery) score
(CSS) could provide prognostic information in addition to original SS. However,
limited data is available about the prognostic value of N-terminal pro-B type natriuretic
peptide (NT-proBNP) in patients with left main (LM) coronary artery bifurcation
lesions. The aim of this study is to assess whether Bio-CSS would improve the ability
to predict mortality compared with CSS in patients undergoing unprotected LM PCI.
Methods: Between June 2006 and December 2012, 225 patients (170 men; mean age
¼ 65.210.9 year-old) underwent unprotected LM stenting were analyzed in this
study. CSS was calculated by multiplying the SS to an ACEF score (age/left ven-
tricular ejection fraction + 1 if serum creatinine >2mg/dL). Bio-CSS was calculated
by multiplying NT-proBNP score (1 for <100 pg/mL, 2 for 100 - <1000 pg/mL, 3 forL/Basic Science, Animal Models and Preclinical Studies S11
